Company profile: Aiolos Bio
1.1 - Company Overview
Company description
- Provider of therapies for respiratory and immune conditions, initially advancing AIO-001, a monoclonal antibody for moderate-to-severe asthma dosed every 6 months. Offers vaccines for meningitis, shingles, RSV, flu, and polio; specialty and general medicines for HIV, asthma, COPD, lupus, cancer, and skin diseases; conducts infectious disease research and develops respiratory/immunology solutions.
Products and services
- Respiratory/Immunology Solutions: Develops medicines for immune-mediated conditions including severe eosinophilic asthma and COPD, initially advancing AIO-001, a monoclonal antibody for moderate-to-severe asthma dosed every 6 months
- Specialty Medicines: Produces first-in-class therapies treating HIV, respiratory diseases, immune-mediated conditions like lupus, and cancer, with products positioned as first or best-in-class across these indications
- Vaccines: Delivers a broad-portfolio range targeting infectious diseases including meningitis, shingles, RSV, flu, and polio, delivered globally
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aiolos Bio
XenoGesis
HQ: United Kingdom
Website
- Description: Provider of preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, and expert interpretation as a specialised CRO.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XenoGesis company profile →
Primrose Bio
HQ: United States
Website
- Description: Provider of biotechnology solutions for discovery, development, and manufacturing of new molecules, including Pfenex Expression Technology for high-yield production of complex proteins, Prima RNApols to enhance mRNA yield and quality, PeliCRM197 carrier protein for conjugate vaccines, the Function Generator for novel gene creation, and EOS for enzymatic DNA/RNA oligonucleotide synthesis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Primrose Bio company profile →
Gentronix
HQ: United Kingdom
Website
- Description: Provider of regulatory genotoxicity studies (GLP Ames, mouse lymphoma, in vitro micronucleus), predictive genotoxicity screening to detect liability early, skin toxicology assays for corrosion, irritation and sensitisation, and flow cytometry services. Includes Ames MPF/II and 24-well Agar formats requiring low test item amounts. Supports drug development and chemicals in cosmetics, personal care, and other chemistry driven industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gentronix company profile →
LGM Pharma
HQ: United States
Website
- Description: Provider of cGMP API sourcing and distribution with integrated supply chain security and regulatory support. Services include CDMO development and manufacturing from concept to commercialization, analytical method development, validation and stability testing, regulatory submissions, logistics for import and clearance, and suppository formulation and manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LGM Pharma company profile →
Uquifa
HQ: Spain
Website
- Description: Provider of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and custom synthesis services for the pharmaceutical industry. Operates three cGMP manufacturing sites (two in Spain, one in Mexico) inspected and approved by major pharmaceutical companies and regulatory authorities, including the US FDA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Uquifa company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aiolos Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aiolos Bio
2.2 - Growth funds investing in similar companies to Aiolos Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aiolos Bio
4.2 - Public trading comparable groups for Aiolos Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →